Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


12.02.2024

5 AJR Am J Roentgenol
8 Ann Surg Oncol
1 Anticancer Res
4 BMC Cancer
1 BMJ
1 Br J Cancer
3 Breast Cancer
5 Breast Cancer Res
3 Breast Cancer Res Treat
1 Breast J
2 Cancer
1 Cancer Chemother Pharmacol
2 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
2 Cancer Res
5 Clin Breast Cancer
1 Clin Med Insights Oncol
3 Eur J Cancer
6 Eur Radiol
2 Int J Cancer
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
2 J Nucl Med
1 Lancet Oncol
1 NPJ Breast Cancer
1 Oncogene
1 Proc Natl Acad Sci U S A
1 Radiol Artif Intell
1 Radiol Cardiothorac Imaging
2 Radiol Imaging Cancer
1 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. CHOU SS
    Editorial Comment: The Time Is Almost Ripe to Mainstream Diffusion in Routine Breast MRI.
    AJR Am J Roentgenol. 2023 Nov 1. doi: 10.2214/AJR.23.30445.
    PubMed        

  2. LANGMAN EL, Johnson KS, Dinome ML
    Retained Biopsy Site Markers After Breast Lesion Surgical Resection: Associations With Residual Malignancy.
    AJR Am J Roentgenol. 2024;222:e2329670.
    PubMed         Abstract available

  3. BUTLER RS
    Editorial Comment: Artificial Intelligence May Help Define Screening Strategies in Patients With Dense Breasts.
    AJR Am J Roentgenol. 2024;222:e2330042.
    PubMed        

  4. LEE SE, Yoon JH, Son NH, Han K, et al
    Screening in Patients With Dense Breasts: Comparison of Mammography, Artificial Intelligence, and Supplementary Ultrasound.
    AJR Am J Roentgenol. 2023 Jul 26. doi: 10.2214/AJR.23.29655.
    PubMed         Abstract available

  5. PHILPOTTS LE
    Beyond the AJR: Patient Cost-Sharing Adversely Affects Adherence to Downstream Imaging After Mammography Screening.
    AJR Am J Roentgenol. 2023 May 31. doi: 10.2214/AJR.23.29685.
    PubMed        


    Ann Surg Oncol

  6. ROLDAN-VASQUEZ E, Bharani T, Mitri S, Flores R, et al
    Expanding Access to Immediate Lymphatic Reconstruction Through an Axillary Surgery Referral Program: A 6-Year Single-Center Experience.
    Ann Surg Oncol. 2024;31:2025-2031.
    PubMed         Abstract available

  7. CARTER MM, Whitrock JN, Pratt CG, Shaughnessy EA, et al
    Nationwide Analysis of Locoregional Management for Ductal Carcinoma In Situ in Males: An NCDB Analysis of the Surgical Approach to DCIS in Males.
    Ann Surg Oncol. 2024;31:1599-1607.
    PubMed         Abstract available

  8. GOLDHABER N, O'Keefe T, Blair S
    Reply to: "Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns.
    Ann Surg Oncol. 2024;31:1669-1670.
    PubMed        

  9. SPIEKERMAN VAN WEEZELENBURG MA, Bakens MJAM, Daemen JHT, Aldenhoven L, et al
    Prevention of Seroma Formation and Its Sequelae After Axillary Lymph Node Dissection: An Up-to-Date Systematic Review and Guideline for Surgeons.
    Ann Surg Oncol. 2024;31:1643-1652.
    PubMed         Abstract available

  10. CHO JH, Park JM, Park HS, Kim HJ, et al
    ASO Visual Abstract: Oncologic Outcomes in Nipple-Sparing Mastectomy with Immediate Reconstruction and Total Mastectomy with Immediate Reconstruction in Women with Breast Cancer: A Machine Learning Analysis.
    Ann Surg Oncol. 2024 Feb 8. doi: 10.1245/s10434-024-14982.
    PubMed        

  11. CARTER MM, Whitrock JN, Pratt CG, Shaughnessy EA, et al
    ASO Visual Abstract: Nationwide Analysis of Locoregional Management for Ductal Carcinoma In Situ (DCIS) in Males-An NCDB Analysis of the Surgical Approach to DCIS in Males.
    Ann Surg Oncol. 2024;31:1663-1664.
    PubMed        

  12. VORSTENBOSCH J, Ghione P, Plitas G, Horwitz S, et al
    Surgical Management and Long-Term Outcomes of BIA-ALCL: A Multidisciplinary Approach.
    Ann Surg Oncol. 2024;31:2032-2040.
    PubMed         Abstract available

  13. PALMQUIST E, Sevilimedu V, Garcia P, Le T, et al
    Patient-Reported Outcomes in Patients Undergoing Lumpectomy With and Without Defect Closure.
    Ann Surg Oncol. 2024;31:1615-1622.
    PubMed         Abstract available


    Anticancer Res

  14. FRITSCH H, Celik M, Warm M, Thangarajah F, et al
    Sonographic Assessment of Breast Implants Using Strain Elastography and Shear Wave Elastography in an Animal Model.
    Anticancer Res. 2024;44:497-501.
    PubMed         Abstract available


    BMC Cancer

  15. JIANG Y, Liu J, Chen L, Qian Z, et al
    A promising target for breast cancer: B7-H3.
    BMC Cancer. 2024;24:182.
    PubMed         Abstract available

  16. KIM MW, Lee H, Lee S, Moon S, et al
    Drug-resistant profiles of extracellular vesicles predict therapeutic response in TNBC patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:185.
    PubMed         Abstract available

  17. LU Y, Hui B, Yang D, Li Y, et al
    Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients.
    BMC Cancer. 2024;24:181.
    PubMed         Abstract available

  18. ABBOAH-OFFEI M, Bayuo J, Salifu Y, Afolabi O, et al
    Experiences and perceptions of men following breast cancer diagnosis: a mixed method systematic review.
    BMC Cancer. 2024;24:179.
    PubMed         Abstract available


    BMJ

  19. FREEMAN K, Jenkinson D, Clements K, Wallis MG, et al
    Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.
    BMJ. 2024;384:e077039.
    PubMed         Abstract available


    Br J Cancer

  20. AXELSEN TV, Olesen C, Khan D, Mohammadi A, et al
    Antibodies toward Na(+),HCO(3)(-)-cotransporter NBCn1/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer.
    Br J Cancer. 2024 Feb 3. doi: 10.1038/s41416-024-02591.
    PubMed         Abstract available


    Breast Cancer

  21. IWAMOTO T, Kumamaru H, Niikura N, Sagara Y, et al
    Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.
    Breast Cancer. 2024 Feb 6. doi: 10.1007/s12282-024-01545.
    PubMed         Abstract available

  22. YU T, Rui L, Jiumei Z, Ziwei L, et al
    Advances in the study of autophagy in breast cancer.
    Breast Cancer. 2024 Feb 5. doi: 10.1007/s12282-023-01541.
    PubMed         Abstract available

  23. ZHUANG JY, Huang ZN, Weng ZJ, Liu MM, et al
    Expression and clinical significance of hypoxia-induced long non-coding RNA TCONS_I2_00001955 in breast cancer.
    Breast Cancer. 2024 Feb 4. doi: 10.1007/s12282-023-01540.
    PubMed         Abstract available


    Breast Cancer Res

  24. LEE J, Nishikawa RM
    Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover.
    Breast Cancer Res. 2024;26:21.
    PubMed         Abstract available

  25. QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
    The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
    Breast Cancer Res. 2024;26:23.
    PubMed         Abstract available

  26. LUNDBERG P, Abrahamsson A, Kihlberg J, Tellman J, et al
    Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women.
    Breast Cancer Res. 2024;26:22.
    PubMed         Abstract available

  27. RONNLUND C, Sifakis EG, Schagerholm C, Yang Q, et al
    Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:24.
    PubMed         Abstract available

  28. SANTERAMO R, Damiani C, Wei J, Montana G, et al
    Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case-control study.
    Breast Cancer Res. 2024;26:25.
    PubMed         Abstract available


    Breast Cancer Res Treat

  29. HWANG YH, Yoo TK, Lee SB, Kim J, et al
    Comparison of long-term oncological outcomes after central lumpectomy versus nipple-sparing breast-conserving surgery for centrally located breast cancer: a propensity score-matched study.
    Breast Cancer Res Treat. 2024 Feb 8. doi: 10.1007/s10549-024-07267.
    PubMed         Abstract available

  30. GOYAL RK, Zhang J, Davis KL, Sluga-O'Callaghan M, et al
    Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
    Breast Cancer Res Treat. 2024 Feb 4. doi: 10.1007/s10549-023-07080.
    PubMed         Abstract available

  31. SIVAKANTHAN T, Tanner J, Mahata B, Agrawal A, et al
    Investigating the role of tumour-to-skin proximity in predicting nodal metastasis in breast cancer.
    Breast Cancer Res Treat. 2024 Feb 3. doi: 10.1007/s10549-023-07230.
    PubMed         Abstract available


    Breast J

  32. DILAVERI C, Degnim A, Lee C, DeSimone D, et al
    Idiopathic Granulomatous Mastitis.
    Breast J. 2024;2024:6693720.
    PubMed         Abstract available


    Cancer

  33. NGUYEN SM, Tran HTT, Long J, Shrubsole MJ, et al
    Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer.
    Cancer. 2024 Feb 6. doi: 10.1002/cncr.35229.
    PubMed         Abstract available

  34. VERSLUIS MAJ, Raijmakers NJH, Baars A, van den Beuken-van Everdingen MHJ, et al
    Trajectories of health-related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study.
    Cancer. 2024;130:609-617.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  35. ELKASAR AO, Hussien FZ, Abdel-Hamied HE, Saleh IG, et al
    Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
    Cancer Chemother Pharmacol. 2024 Feb 7. doi: 10.1007/s00280-023-04620.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  36. PEILA R, Rohan TE
    Metabolic Syndrome and the Risk of Ductal Carcinoma In Situ of the Breast in the UK Biobank.
    Cancer Epidemiol Biomarkers Prev. 2024;33:333-336.
    PubMed         Abstract available

  37. DEVASIA TP, Howlader N, Dewar RA, Stevens JL, et al
    Increase in the Life Expectancy of Patients with Cancer in the United States.
    Cancer Epidemiol Biomarkers Prev. 2024;33:196-205.
    PubMed         Abstract available


    Cancer Lett

  38. TAN Z, Boyapati K, Tressler CM, Jenkinson N, et al
    Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3beta/beta-catenin/EMT pathway.
    Cancer Lett. 2024 Feb 1:216653. doi: 10.1016/j.canlet.2024.216653.
    PubMed         Abstract available

  39. BAHREYNI A, Mohamud Y, Luo H
    Oncolytic virus-based combination therapy in breast cancer.
    Cancer Lett. 2024 Feb 1:216634. doi: 10.1016/j.canlet.2024.216634.
    PubMed         Abstract available


    Cancer Res

  40. GEDIK ME, Saatci O, Oberholtzer N, Uner M, et al
    Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer.
    Cancer Res. 2024 Feb 6. doi: 10.1158/0008-5472.CAN-23-2812.
    PubMed         Abstract available

  41. BERNARD MJ, Goldstein AS
    A metabolic-epigenetic mechanism directs cell fate and therapeutic sensitivity in breast cancer.
    Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0460.
    PubMed         Abstract available


    Clin Breast Cancer

  42. KNOWLES AJ
    Advocating for Enhanced Patient Engagement in Breast Cancer Care: Impact of Residual Increased Lateral Adiposity and Consideration of the Pursuit of "Living Flat".
    Clin Breast Cancer. 2024 Jan 17:S1526-8209(24)00003.
    PubMed         Abstract available

  43. PLOUMAKI I, Triantafyllou E, Koumprentziotis IA, Karampinos K, et al
    Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
    Clin Breast Cancer. 2024 Jan 16:S1526-8209(24)00002.
    PubMed         Abstract available

  44. XU J, Gan C, Yu S, Yao S, et al
    Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
    Clin Breast Cancer. 2024;24:e91-e102.
    PubMed         Abstract available

  45. WANG Y, Peng D, Zhou X, Hu W, et al
    Treatments and Prognosis of the Breast Ductal Carcinoma In Situ.
    Clin Breast Cancer. 2024;24:122-130.
    PubMed         Abstract available

  46. MOKBEL K
    Unlocking the Power of the Homing Phenomenon: Why Breast Conserving Surgery Outshines Mastectomy in Overall Survival.
    Clin Breast Cancer. 2024;24:85-92.
    PubMed         Abstract available


    Clin Med Insights Oncol

  47. HASONA NA, Elsabahy M, Shaker OG, Zaki O, et al
    The Implication of Growth Arrest-Specific 5 rs145204276 Polymorphism and Serum Expression of Sirtuin 1, Transforming Growth Factor-Beta, and microRNA-182 in Breast Cancer.
    Clin Med Insights Oncol. 2024;18:11795549241227415.
    PubMed         Abstract available


    Eur J Cancer

  48. YANG F, Liu G, Mao F, Zheng YC, et al
    Corrigendum to "Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer"
    Eur J Cancer. 2024 Feb 2:113559. doi: 10.1016/j.ejca.2024.113559.
    PubMed        

  49. RUSAKIEWICZ S, Tyekucheva S, Tissot-Renaud S, Chaba K, et al
    Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Eur J Cancer. 2024;200:113535.
    PubMed         Abstract available

  50. DIERAS V, Han HS, Wildiers H, Friedlander M, et al
    Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.
    Eur J Cancer. 2024;200:113580.
    PubMed         Abstract available


    Eur Radiol

  51. ZHAO S, Li Y, Ning N, Liang H, et al
    Association of peritumoral region features assessed on breast MRI and prognosis of breast cancer: a systematic review and meta-analysis.
    Eur Radiol. 2024 Feb 9. doi: 10.1007/s00330-024-10612.
    PubMed         Abstract available

  52. TONG Y, Hu Z, Wang H, Huang J, et al
    Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model.
    Eur Radiol. 2024 Feb 8. doi: 10.1007/s00330-024-10609.
    PubMed         Abstract available

  53. MULLEN LA
    Can digital breast tomosynthesis decrease interval cancers in a breast cancer screening program?
    Eur Radiol. 2024 Feb 6. doi: 10.1007/s00330-024-10635.
    PubMed        

  54. ZHANG T, Mann RM
    Contrast-enhanced mammography: better with AI?
    Eur Radiol. 2024;34:914-916.
    PubMed        

  55. XU J, Zhang L, Wen W, He Y, et al
    Evaluation of standard breast ultrasonography by adding two-dimensional and three-dimensional shear wave elastography: a prospective, multicenter trial.
    Eur Radiol. 2024;34:945-956.
    PubMed         Abstract available

  56. BARR RG
    Breast elastography: how does it works, and for what purposes?
    Eur Radiol. 2024;34:928-929.
    PubMed        


    Int J Cancer

  57. SVANOE AA, Humlevik ROC, Knutsvik G, Saele AKM, et al
    Age-related phenotypes in breast cancer: A population-based study.
    Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34863.
    PubMed         Abstract available

  58. PEILA R, Rohan TE
    Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study.
    Int J Cancer. 2024;154:1191-1203.
    PubMed         Abstract available


    Int J Oncol

  59. ZHANG W, Tang X, Peng Y, Xu Y, et al
    GBP2 enhances paclitaxel sensitivity in triple?negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.
    Int J Oncol. 2024;64:34.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  60. PETRY V, Bonadio RC, Moutinho K, Leite LS, et al
    Frequency of radiotherapy-induced malignancies in Li-Fraumeni Syndrome patients with early-stage breast cancer and influence of the radiotherapy technique.
    Int J Radiat Oncol Biol Phys. 2024 Feb 1:S0360-3016(24)00249.
    PubMed         Abstract available


    J Nucl Med

  61. GEBHART G, Piccart M, Mankoff D
    Molecular Imaging in Breast Cancer: Martine Piccart and Geraldine Gebhart Talk with David Mankoff About 2 Generations of Research.
    J Nucl Med. 2024 Feb 8:jnumed.124.267461. doi: 10.2967/jnumed.124.267461.
    PubMed        

  62. GONDRY O, Caveliers V, Xavier C, Raes L, et al
    Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
    J Nucl Med. 2024;65:178-184.
    PubMed         Abstract available


    Lancet Oncol

  63. BAJPAI J, Kapu V, Rath S, Kumar S, et al
    Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled,
    Lancet Oncol. 2024;25:246-254.
    PubMed         Abstract available


    NPJ Breast Cancer

  64. FABI A, Carbognin L, Botticelli A, Paris I, et al
    Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
    NPJ Breast Cancer. 2024;10:13.
    PubMed        


    Oncogene

  65. LAGARDE CB, Kavalakatt J, Benz MC, Hawes ML, et al
    Obesity-associated epigenetic alterations and the obesity-breast cancer axis.
    Oncogene. 2024 Feb 3. doi: 10.1038/s41388-024-02954.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  66. LI SY, Hammarlund JA, Wu G, Lian JW, et al
    Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2311854121.
    PubMed         Abstract available


    Radiol Artif Intell

  67. KIM JG, Haslam B, Diab AR, Sakhare A, et al
    Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists.
    Radiol Artif Intell. 2024 Feb 7:e230137. doi: 10.1148/ryai.230137.
    PubMed         Abstract available


    Radiol Cardiothorac Imaging

  68. HONG YJ, Han K, Lee HJ, Hur J, et al
    Assessment of Feasibility and Interscan Variability of Short-time Cardiac MRI for Cardiotoxicity Evaluation in Breast Cancer.
    Radiol Cardiothorac Imaging. 2024;6:e220229.
    PubMed         Abstract available


    Radiol Imaging Cancer

  69. FREITAS V, Li X, Scaranelo A, Au F, et al
    Breast Cancer Detection Using a Low-Dose Positron Emission Digital Mammography System.
    Radiol Imaging Cancer. 2024;6:e230020.
    PubMed         Abstract available

  70. BARRETO DS, Rapelyea JA
    Low-Dose Positron Emission Mammography: A Novel, Promising Technique for Breast Cancer Detection.
    Radiol Imaging Cancer. 2024;6:e240006.
    PubMed        


    Radiother Oncol

  71. RAUFF SONDERGAARD S, Bechmann T, Maae E, Molby Nielsen AW, et al
    Shared decision making with breast cancer patients - does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial.
    Radiother Oncol. 2024 Feb 3:110115. doi: 10.1016/j.radonc.2024.110115.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.